Fundraising Fox6 Dimensions Capital — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues.
AI & Machine LearningBiotechLongevity
Tamer Mohamed(Founder & CEO)inSam Wadsworth(Co-founder & Chief Scientific Officer)inSimon Beyer(Co-founder & Chief Technology Officer)inLeela Paris(Chief Technical Operations Officer)inMike Scott(Chief Development Officer)inRay Smith(Chief Financial Officer)in
Co-investorsAngel ForumCivilization Ventures Management, LlcInBC Investment Corp.JDRF T1D FundPage One VenturesPallasite Ventures+6 more
Convoke offers an AI platform that ingests and structures data from documents, scientific literature, SEC filings, and clinical data, and deploys custom agents to automate knowledge tasks and generate reports, manuscripts, and landscape analyses.
AI & Machine LearningBiotechEnterprise SoftwareHealthtechSaaS
Co-investorsAudaciousKleiner PerkinsACMEComma CapitalDimension CapitalLux Capital+2 more
Fiveonefour builds tooling focused on agent experience (AX), helping developers ship software that AI agents can use effectively.
AI & Machine LearningDeveloper ToolsSaaSPortland, US
Timote Gelinas Delisle(Executive Officer, Director, Promoter)Chris Crane(Founder)inNicolas Joseph(Founder)in
Co-investorsFlybridge Capital PartnersVermilion Cliffs VenturesDimension CapitalRidge VenturesStage 2 Capital
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)in
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in
Co-investorsActivant CapitalAscenta CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess Fund+8 more
Verisian builds software for clinical research and public health authorities to analyze and monitor clinical trial data in real-time, improving decision-making and trial safety.
BiotechDigital HealthHealthtechSaaS
BoardSunil Gupta(Strategic Advisor)
Co-investorsCambridge Angels groupRecode VenturesSuperSeedManchesterStory Group, LLC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.